Arix Bioscience Plc (LON:ARIX) Chairman Jonathan Peacock and Investment Director Daniel O'Connell tell Proactive Investors the health care and life science company has formed LAB591, an academic "BRIDGE" collaboration with the Fred Hutchinson Cancer Research Center in Seattle, Washington, and drug discovery alliance and development partnership company Evotec AG (OTCMKTS:EVTCY).
According to Arix, LAB591 aims to accelerate research discoveries at Fred Hutch and use these discoveries to form new companies focused on cancer and infectious disease drug development.